BAROCCO: A randomized phase II study of weekly paclitaxel vs cediranib-olaparib with continuous schedule vs cediranib-olaparib with intermittent schedule in advanced platinum resistant ovarian cancer

BAROCCO: A randomized phase II study of weekly paclitaxel vs cediranib-olaparib combination given with continuous or intermittent schedule in patients with recurrent platinum resistant ovarian cancer (PROC)

Annals of Oncology ◽

10.1093/annonc/mdz394.055 ◽

2019 ◽

Vol 30 ◽

pp. v896 ◽

Cited By ~ 3

Author(s):

N. Colombo ◽

M.O. Nicoletto ◽

P. Benedetti Panici ◽

G. Tognon ◽

A. Bologna ◽

...

Keyword(s):

Ovarian Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Weekly Paclitaxel ◽

Intermittent Schedule ◽

Platinum Resistant ◽

Epigenetic resensitization to platinum in recurrent, platinum-resistant ovarian cancer (OC) using guadecitabine (SGI-110), a novel hypomethylating agent (HMA): Results of a randomized phase II study.

Journal of Clinical Oncology ◽

10.1200/jco.2016.34.15_suppl.5547 ◽

2016 ◽

Vol 34 (15_suppl) ◽

pp. 5547-5547 ◽

Cited By ~ 5

Author(s):

Ursula A. Matulonis ◽

Amit M. Oza ◽

Angeles Alvarez Secord ◽

Lynda D. Roman ◽

Sarah Patricia Blagden ◽

...

Keyword(s):

Ovarian Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Hypomethylating Agent ◽

Platinum Resistant ◽

Phase II study of gemcitabine and weekly paclitaxel in recurrent platinum-resistant ovarian cancer

Gynecologic Oncology ◽

10.1016/j.ygyno.2004.02.007 ◽

2004 ◽

Vol 93 (2) ◽

pp. 493-498 ◽

Cited By ~ 28

Author(s):

A GARCIA ◽

A OMEARA ◽

A BAHADOR ◽

G FACIO ◽

S JEFFERS ◽

...

Keyword(s):

Ovarian Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Weekly Paclitaxel ◽

Randomized phase II study of the PDGFRα antibody olaratumab plus liposomal doxorubicin versus liposomal doxorubicin alone in patients with platinum-refractory or platinum-resistant advanced ovarian cancer

BMC Cancer ◽

10.1186/s12885-018-5198-4 ◽

2018 ◽

Vol 18 (1) ◽

Cited By ~ 10

Author(s):

William P. McGuire ◽

Richard T. Penson ◽

Martin Gore ◽

Antonio Casado Herraez ◽

Patrick Peterson ◽

...

Keyword(s):

Ovarian Cancer ◽

Phase Ii ◽

Liposomal Doxorubicin ◽

Phase Ii Study ◽

Advanced Ovarian Cancer ◽

Platinum Resistant ◽

Randomized Phase Ii ◽

Platinum Refractory

A randomized, double-blind, placebo-controlled phase II study of the efficacy and safety of farletuzumab (MORAb-003) in combination with weekly paclitaxel in subjects with platinum-resistant or refractory relapsed ovarian cancer.

Journal of Clinical Oncology ◽

10.1200/jco.2010.28.15_suppl.tps255 ◽

2010 ◽

Vol 28 (15_suppl) ◽

pp. TPS255-TPS255 ◽

Cited By ~ 3

Author(s):

L. Elit ◽

J. A. Konner ◽

D. K. Armstrong ◽

M. Buck ◽

A. Dean ◽

...

Keyword(s):

Ovarian Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Weekly Paclitaxel ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo ◽

Faculty Opinions recommendation of PRECEDENT: a randomized phase II trial comparing vintafolide (EC145) and pegylated liposomal doxorubicin (PLD) in combination versus PLD alone in patients with platinum-resistant ovarian cancer.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718144304.793486590 ◽

2013 ◽

Author(s):

Roberto Angioli

Keyword(s):

Ovarian Cancer ◽

Phase Ii ◽

Liposomal Doxorubicin ◽

Phase Ii Trial ◽

Pegylated Liposomal Doxorubicin ◽

Platinum Resistant ◽

Phase II study of cetrorelix, a luteinizing hormone-releasing hormone antagonist in patients with platinum-resistant ovarian cancer

The Women s Oncology Review ◽

10.3109/14733400410001669533 ◽

2004 ◽

Vol 4 (1) ◽

pp. 45-46

Author(s):

Agustin Garcia

Keyword(s):

Ovarian Cancer ◽

Luteinizing Hormone ◽

Phase Ii ◽

Phase Ii Study ◽

Luteinizing Hormone Releasing Hormone ◽

Releasing Hormone ◽

A phase II study of single-agent RO4929097, a gamma-secretase inhibitor of Notch signaling, in patients with recurrent platinum-resistant epithelial ovarian cancer: A study of the Princess Margaret, Chicago and California phase II consortia

Gynecologic Oncology ◽

10.1016/j.ygyno.2015.03.005 ◽

2015 ◽

Vol 137 (2) ◽

pp. 216-222 ◽

Cited By ~ 32

Author(s):

Ivan Diaz-Padilla ◽

Michelle K. Wilson ◽

Blaise A. Clarke ◽

Hal W. Hirte ◽

Stephen A. Welch ◽

...

Keyword(s):

Ovarian Cancer ◽

Epithelial Ovarian Cancer ◽

Notch Signaling ◽

Phase Ii ◽

Phase Ii Study ◽

Single Agent ◽

Gamma Secretase ◽

Platinum Resistant ◽

Secretase Inhibitor ◽

Gamma Secretase Inhibitor

A multicenter phase II study of the cryptophycin analog LY355703 in patients with platinum-resistant ovarian cancer

International Journal of Gynecological Cancer ◽

10.1111/j.1525-1438.2006.00276.x ◽

2006 ◽

Vol 16 (1) ◽

pp. 71-76 ◽

Cited By ~ 55

Author(s):

G D'AGOSTINO ◽

J DEL CAMPO ◽

B MELLADO ◽

M.A. IZQUIERDO ◽

T MINARIK ◽

...

Keyword(s):

Ovarian Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Multicenter Phase ◽

Lurbinectedin (PM01183) Activity in Platinum-Resistant/Refractory Ovarian Cancer Patients. Preliminary Results of an Ongoing Two-Stage Phase II Study

Annals of Oncology ◽

10.1016/s0923-7534(20)34332-5 ◽

2012 ◽

Vol 23 ◽

pp. ixe17

Author(s):

D. Berton-Rigaud ◽

J. Alexandre ◽

M. Provansal ◽

A. Casado ◽

A. Gonzalez Martin ◽

...

Keyword(s):

Ovarian Cancer ◽

Cancer Patients ◽

Phase Ii ◽

Phase Ii Study ◽

Two Stage ◽

Preliminary Results ◽

Resistant Refractory ◽